BOLT (Bolt Biotherapeutics) Forward P/E Multiple
The forward P/E ratio for Bolt Biotherapeutics (BOLT), as presented by the GURU.Markets platform, reflects a period of austerity and frozen development for Bolt Biotherapeutics (BOLT). Meanwhile, 0.00 serves as the current level of this metric. The company is implementing unique ISAC-conjugates to combat cancer by leveraging innate immunity; however, business success depends on confirming the efficacy of solid tumor therapies and securing strategic partnerships.
Analytical breakdowns for Bolt Biotherapeutics
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- debt and liquidity details:
Total Debt to Equity Ratio Bolt Biotherapeutics|BOLT - Long-Term Debt to Capital|Short-Term Debt to Equity Bolt Biotherapeutics|BOLT - Company Aggregate Debt|Debts to Book Capitalization Bolt Biotherapeutics Inc.|BOLT - Long-Term Debt|Company Short-Term Debts Bolt Biotherapeutics|Quick Liquidity boltbio.com
- company profitability and valuation multiples indicators:
BOLT - Company Net Income|Expected Profit Bolt Biotherapeutics|BOLT - Price to Earnings Ratio|Projected Price to Earnings Bolt Biotherapeutics|BOLT - Company Value to Earnings Growth Ratio|Enterprise Value to EBITDA Ratio Bolt Biotherapeutics Inc.|BOLT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Bolt Biotherapeutics|BOLT - Earnings per share for the last twelve months|Quarterly EPS earnings growth boltbio.com|BOLT - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Bolt Biotherapeutics
- total revenue and sales volume data:
Summary company analytics:Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is developing innovative ISAC platforms to combat cancer, making the company's forward P/E a key indicator of market expectations regarding its capitalization relative to projected earnings. Analyzing this chart, an investor assesses the ratio of current share price to expected income, adjusted for tax liabilities and the impact of strategic payments from pharma partners, to determine the extent of the asset's premium.
Competitors of Bolt Biotherapeutics (BOLT)
Projected Price to Earnings ARGX (argenx)|BNTX (BioNTech Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple ABVX (abivax.com)|Market Cap to Projected Earnings ADMA Corp (ADMA)|PTGX - Future Price to Earnings|immunovant.com (IMVT) - Projected Price to Earnings|Kiniksa (KNSA) - Future Price to Earnings|Projected Price to Earnings Grifols SA|Projected Price to Earnings ADPT|Forward P/E Multiple Celldex Corp|Future Price to Earnings Aurinia Pharmaceuticals (AUPH)|biocryst.com - Price to Future Earnings Ratio|Forward P/E Multiple VERA (Vera Therapeutics)|Dianthus Therapeutics Inc (DNTH) - Projected Price to Earnings Ratio|Pharvaris Corp - Forward P/E Multiple|ABCL: Future Price to Earnings|Tourmaline Bio, Inc. (TRML) - Future Price to Earnings|Projected Price to Earnings Ratio precigen.com (PGEN)|Future Price to Earnings Pharming Group|Future Price to Earnings NKTR|Projected Price to Earnings UPB (Upstream Bio Corp)|Market Cap to Future Earnings Ratio ZBIO|Immunome, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple GOSS|KalVista Pharmaceuticals, Inc. - Forward P/E Multiple|SEPN: Future Price to Earnings|PVLA: Forward P/E Multiple|SVRA - Market Cap to Projected Earnings|Future Price to Earnings Rigel Pharmaceuticals|Projected Price to Earnings Ratio anaptysbio.com ANAB|Projected Price to Earnings ATXS (Astria Therapeutics, Inc.)|Market Cap to Future Earnings Ratio ENGN|Forward P/E Multiple RAPT (RAPT Therapeutics, Inc.)|Future Price to Earnings Multiple JBIO|Aclaris Therapeutics - Forward P/E Multiple|Projected Price to Earnings Ratio kyvernatx.com|Tiziana Life Sciences Ltd (TLSA) - Future Price to Earnings|Cabaletta Bio Inc. - Future Price to Earnings Multiple|VTYX (Ventyx Bio) - Forward P/E Multiple|Forward P/E Multiple Theratechnologies, Inc|Future Price to Earnings Avalo Therapeutics, Inc (AVTX)|ELDN: Price to Expected Earnings Ratio|Forward P/E Multiple AGEN (Agenus Inc.)|Climb Bio Inc. (CLYM) - Projected Price to Earnings Ratio|ZURA: Projected Price to Earnings|ATYR - Forward P/E Multiple|ADAG (adagene.com) - Projected Price to Earnings|IMA: Market Cap to Future Earnings Ratio|STTK (Shattuck Labs Inc) - Forward P/E Multiple|Equillium Bio (EQ) - Market Cap to Projected Earnings|Forward P/E Multiple CNTB|Projected Price to Earnings immunic-therapeutics.com IMUX|Future Price to Earnings Atara Bio ATRA|Market Cap to Projected Earnings InflaRx NV (IFRX)|X4 Pharmaceuticals, Inc. - Forward P/E Multiple|ACET: Future Price to Earnings|celularity.com (CELU) - Future Price to Earnings|Projected Price to Earnings Ratio INmune Bio Corporation (INMB)|Future Price to Earnings Barinthus Biotherapeutics|Future Price to Earnings KZR|Projected Price to Earnings SABS (SAB Biotherapeutics, Inc.)|Market Cap to Future Earnings Ratio AKTX|Future Price to Earnings Enlivex Therapeutics Ltd. ENLV|QTTB (Q32 Bio Inc) - Price to Expected Earnings Ratio|GeoVax Labs, Inc. - Forward P/E Multiple|Future Price to Earnings Multiple EDSA (edesabiotech.com)|IBIO: Forward P/E Multiple|Carisma Therapeutics Inc. (CARM) - Forward P/E Multiple|Future Price to Earnings XTL Biopharmaceuticals, Ltd.|HCWB: Future Price to Earnings Multiple|Future Price to Earnings Aptevo Therapeutics (APVO)|Projected Price to Earnings AIM ImmunoTech, Inc. AIM|Forward P/E Multiple ADTX (Aditxt, Inc.)|Forward P/E Multiple GRI Bio Inc GRI|XRTX: Projected Price to Earnings|Future Price to Earnings Multiple HIND (Vyome Therapeutics)|REVB: Forward P/E Multiple|INDP - Market Cap to Projected Earnings|Future Price to Earnings Scinai Immunotherapeutics Ltd.|Projected Price to Earnings CalciMedica Corp (CALI)|Future Price to Earnings Affimed (AFMD)|Projected Price to Earnings allakos.com ALLK|HOOKIPA Pharma - Projected Price to Earnings|Forward P/E Multiple IGM Biosciences Inc. IGMS|ITOS - Future Price to Earnings|OCEA (Ocean Biomedical Inc) - Price to Future Earnings Ratio|TCBP: Forward P/E Multiple|Projected Price to Earnings Ratio Third Harmonic Bio Inc (THRD)
